Recursion Pharmaceuticals RXRX
$2.45 −$0.27 (-9.93%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $2.51 +2.39%
Open$2.63
Prev close$2.72
Day range$2.44 – $2.76
Volume29.88M
Market cap$1.53B
P/E (TTM)–
Dividend yield–
RXRX Stock News
Headlines matching Recursion Pharmaceuticals or the RXRX ticker, most recent first.
- BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
- Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Recursion Pharmaceuticals (RXRX), Teladoc (TDOC) and Oscar Health (OSCR)
- J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating
- Recursion Pharmaceuticals (RXRX) Gets a Hold From Bank of America Securities
- TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
- Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $8
- Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5.3 Negative
- BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $6
- Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Raises Target Price to $5.5 Positive
- J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $10 Negative
- BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $6 Negative
- Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake
- News Flash: Analysts Just Made A Meaningful Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts Positive
- Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hassan Fred
No comments yet — be the first to weigh in on RXRX.
Sign in to join the discussion.